Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute, National Health Committee Key Laboratory of Hypertension Clinical Research, Urumqi, Xinjiang 830001, China.
Biomed Res Int. 2021 Apr 30;2021:6637235. doi: 10.1155/2021/6637235. eCollection 2021.
Systemic vasculitis includes a group of disorders characterized by inflammation of the vessel wall, involving multiple systems, and can cause malignant hypertension. CD163 is a specific marker of anti-inflammatory macrophages. This study is aimed at evaluating the CD163 levels in relation to systemic vasculitis and renal involvements.
Urinary CD163 levels were retrospectively measured by enzyme-linked immunosorbent assay (ELISA) in 51 patients with systemic vasculitis, 42 essential hypertensions, and 36 healthy volunteers. The associations between urinary CD163 levels and clinical indicators were analyzed.
Urinary CD163 levels were significantly higher in patients with systemic vasculitis [68.20 (38.25~158.78) (pg/ml)] compared to essential hypertension [43.86 (23.30-60.71) (pg/ml)] ( = 0.003) and the healthy volunteers [30.76 (9.30-54.16) (pg/ml)] ( < 0.001). Furthermore, systemic vasculitis patients with renal involvement had significantly higher urinary CD163 levels relative to patients without renal involvement [86.95 (47.61 and 192.38) pg/ml] vs. [41.99 (17.70 and 71.95) pg/ml, = 0.005]. After control factors age, sex, and BMI, urinary CD163 levels in systemic vasculitis patients were positively correlated with serum creatinine, blood urea nitrogen, and -2 microglobulin ( = 0.45, 0.48, and 0.46; = 0.001, 0.001, and 0.002, respectively). In addition, we found the level of urinary CD163 in granulomatous vasculitis (including TA, GPA, and EGPA) was significantly higher than that in necrotizing vasculitis (including PAN) [86.95 (41.99 and 184.82) pg/ml] vs. [45.73 (21.43 and 74.43) pg/ml, = 0.016].
Urinary CD163 levels were significantly higher in patients with systemic vasculitis, especially in patients with renal involvement. Thus, urinary CD163 has the potential to be a biomarker for systemic vasculitis with renal involvement.
系统性血管炎是一组以血管壁炎症为特征的疾病，涉及多个系统，并可导致恶性高血压。CD163 是抗炎巨噬细胞的特异性标志物。本研究旨在评估 CD163 水平与系统性血管炎和肾脏受累的关系。
采用酶联免疫吸附试验（ELISA）法检测 51 例系统性血管炎、42 例原发性高血压和 36 例健康志愿者的尿 CD163 水平。分析尿 CD163 水平与临床指标的相关性。
系统性血管炎患者尿 CD163 水平[68.20（38.25158.78）（pg/ml）]明显高于原发性高血压患者[43.86（23.3060.71）（pg/ml）]（ = 0.003）和健康志愿者[30.76（9.30~54.16）（pg/ml）]（ < 0.001）。此外，有肾脏受累的系统性血管炎患者尿 CD163 水平明显高于无肾脏受累的患者[86.95（47.61 和 192.38）pg/ml]与[41.99（17.70 和 71.95）pg/ml， = 0.005]。在控制年龄、性别和 BMI 等因素后，系统性血管炎患者尿 CD163 水平与血清肌酐、血尿素氮和β2 微球蛋白呈正相关（ = 0.45、0.48 和 0.46； = 0.001、0.001 和 0.002）。此外，我们发现肉芽肿性血管炎（包括 TA、GPA 和 EGPA）患者尿 CD163 水平明显高于坏死性血管炎（包括 PAN）患者[86.95（41.99 和 184.82）pg/ml]与[45.73（21.43 和 74.43）pg/ml， = 0.016]。
系统性血管炎患者尿 CD163 水平明显升高，尤其是有肾脏受累的患者。因此，尿 CD163 可能成为有肾脏受累的系统性血管炎的生物标志物。
